Reported Sunday, Taiho And Cullinan's REZILIENT3 Trial Meets Primary Endpoint, Zipalertinib Combination Shows PFS Hazard Ratio Of 0.50 Versus Chemotherapy Alone

Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion mutation NSCLC at a planned interim analysis